MedPath

JIMRO CO., LTD.

JIMRO CO., LTD. logo
🇯🇵Japan
Ownership
Subsidiary
Established
1977-11-08
Employees
101
Market Cap
-
Website
http://www.jimro.co.jp

Clinical Trials

5

Active:0
Completed:5

Trial Phases

3 Phases

Phase 2:2
Phase 3:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (40.0%)
Phase 2
2 (40.0%)
Phase 3
1 (20.0%)

Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions

Not Applicable
Completed
Conditions
Coronary Artery Disease
First Posted Date
2017-06-16
Last Posted Date
2025-03-14
Lead Sponsor
JIMRO Co., Ltd.
Target Recruit Count
30
Registration Number
NCT03189641
Locations
🇯🇵

Tokai University Hospital, Isehara, Kanagawa, Japan

🇯🇵

Kitasato University Hospital, Sagamihara, Kanagawa, Japan

🇯🇵

Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan

and more 3 locations

Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)

Not Applicable
Completed
Conditions
Acute Ischemic Stroke
First Posted Date
2016-11-16
Last Posted Date
2019-07-18
Lead Sponsor
JIMRO Co., Ltd.
Target Recruit Count
50
Registration Number
NCT02964702
Locations
🇯🇵

Kurume University Hospital, Kurume, Fukuoka, Japan

🇯🇵

Brain Attack Center Ota Memorial Hospital, Fukuyama, Hiroshima, Japan

🇯🇵

Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

and more 10 locations

Renal Denervation on Quality of 24-hr BP Control by Ultrasound In Resistant Hypertension

Phase 3
Completed
Conditions
Hypertension
Vascular Diseases
First Posted Date
2016-09-28
Last Posted Date
2021-11-19
Lead Sponsor
JIMRO Co., Ltd.
Target Recruit Count
140
Registration Number
NCT02918305

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.